| Description | This product is a monoclonal antibody derived from Human (Homo sapiens), which can specifically recognize Interleukin 17A. The antibody is expressed with mammalian cell transient expression system, serum-free and purified by affinity chromatography. The purity and integrity are tested via SDS-PAGE and SEC-HPLC analysis. Given an antigen, additional QC measures are also desired such as affinity testing and binding validation. Specifically, the antibody is provided in multiple formats for in vivo and in vitro assays. The Invivo version features greater than 95% purity, ultra-low endotoxin levels (<1 EU/mg or 0.1 EU/mg), and is preservative, stabilizer, and carrier protein-free. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | Human, Mouse, Rat |
| Affinity | KD = 5.7 pM, determined by surface plasmon resonance. |
| Isotype | IgG |
| Expression Species | HEK293F or CHO |
| Conjugation | None |
| Purity | >95%, determined by SDS-PAGE and/or SEC-HPLC |
| Endotoxin | <1 EU/mg, determined by LAL method |
| Purification | Protein A affinity purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4⁰C within a week. For longer storage, aliquot and store at -20⁰C. |
| Application | WB; DB; ELISA; FuncS |
| Application Notes | The antibody is recommended for detection of IL17A by ELISA, FuncS assays. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | IL17A |
| Alternative Name | IL17; CTLA8; IL-17; CTLA-8; IL-17A |
| Gene ID | 3605 |
| UniProt | Q16552 |
| Research Area | Cardiovascular; Immunology |
| Related Disease | Rheumatoid arthritis, psoriasis, systemic lupus erythematosus, lupus nephritis, chronic obstructive pulmonary disease, asthma or cystic fibrosis or other autoimmune and inflammatory disorders |
Figure 1 Anti-IL17A Monoclonal Antibody (V3S-0522-YC6568) in SDS-PAGE
SDS-PAGE analysis of V3S-0522-YC6568 in β-mercaptoethanol-reduced conditions. Gel stained for 30 minutes with Coomassie Blue. As a result of different β-mercaptoethanol-reduced proteins (Heavy chain and Light chain) migrate as about 50 kDa and 25 kDa, respectively.
Figure 1 Anti-IL17A Monoclonal Antibody (V3S-0522-YC6568) in SDS-PAGE
Figure 2 Anti-IL17A Monoclonal Antibody (V3S-0522-YC6568) in SEC-HPLC
The purity of V3S-0522-YC6568 was greater than 95% as determined by SEC-HPLC.
Column: 3 µm, 7.8 x 300 nm
Mobile phase: 150 mM Sodium Phosphate Buffer, pH 7.0
Detection: UV 280 nm
Injection: 10 µl
Figure 2 Anti-IL17A Monoclonal Antibody (V3S-0522-YC6568) in SEC-HPLC
Figure 3 Anti-IL17A Monoclonal Antibody (V3S-0522-YC6568) in WB
Western blot analysis of V3S-0522-YC6568 (1:500) was performed by loading human IL17A (aa 1-155). The HRP-Anti-Human IgG (H+L) (1: 6000) as a secondary antibody.
Lane 1: Reducing Antigen (0.1 μg)
Lane 2: Reducing Antigen (0.4 μg)
Lane 3: Reducing Antigen (0.8 μg)
Figure 3 Anti-IL17A Monoclonal Antibody (V3S-0522-YC6568) in WB
Figure 4 Anti-IL17A Monoclonal Antibody (V3S-0522-YC6568) in DB
Dot Blot analysis of V3S-0522-YC6568 (1:500) was performed by coating with human IL17A (aa 1-155). The HRP-Anti-Human IgG (H+L) (1: 6000) as a secondary antibody.
Figure 4 Anti-IL17A Monoclonal Antibody (V3S-0522-YC6568) in DB
Figure 5 Anti-IL17A Monoclonal Antibody (V3S-0522-YC6568) in ELISA
ELISA analysis of V3S-0522-YC6568 was performed by coating human IL17A (aa 1-155). The HRP-Anti-Human IgG (H+L) (1: 4000) as a secondary antibody.
Figure 5 Anti-IL17A Monoclonal Antibody (V3S-0522-YC6568) in ELISA
